There are two types of lung cancer non-small cell and small cell lung cancer. Smoking is very strongly associated with small cell lung cancer. The diagnosis can be made by bronchoscopy, biopsy and PET scan. This cancer has a very high chance of spreading to the brain.

Dr. Randeep Singh, Director & Senior Consultant - Medical Oncology at Narayana Superspeciality Hospital, Gurugram, talks about Small Cell Lung Cancer.

#NarayanaHealth #HealthForAll #AllForHealth #NHCares

For video consultation with the doctor, log on to https://bit.ly/2z7Y0Bd.

Visit our website https://www.narayanahealth.org to know more about Narayana Health and its facilities.

Connect with us:
Facebook - https://www.facebook.com/NarayanaHealth/
Instagram - https://www.instagram.com/narayanahealthindia/
Twitter - https://twitter.com/narayanahealth
Blog - https://www.narayanahealth.org/blog/
LinkedIn - https://www.linkedin.com/company/narayanahealth
Quora - https://www.quora.com/profile/Narayana-Health
Telegram - https://t.me/NarayanaHealth

Time Stamps:
0:00 - Introduction
0:35 - Types Of Lung Cancer
1:06 - Diagnosis of Small Cell Lung Cancer
2:30 - Treatment of Small Cell Lung Cancer

Experts in thoracic oncology share how they treat non–small cell lung cancer with an EGFR exon 20 insertion in clinical practice, as well as with clinical trials.

Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive

Presenting the standard treatment options for patients diagnosed with small cell lung cancer.

View more at http://curetoday.com/

CURE: Combining science and humanity to make cancer understandable.

A discussion on the advances in treatment options for extensive stage small cell lung cancer.

View more at http://curetoday.com/

CURE: Combining science and humanity to make cancer understandable.

In this presentation, Rosanne Janssens (KU Leuven) shares the findings from the qualitative study that was part of the PREFER case study on lung cancer. The recording was made 13 January 2022, and the presentation was part of the PREFER webinar on patient preferences for non-small-cell lung cancer treatment options.

Watch the full webinar: https://youtu.be/1T9bpr3B06A
For more information about the project visit https://www.imi-prefer.eu/

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

This video and its contents reflect the PREFER project's view and not the view of IMI, the European Union or EFPIA.

Discussing the management of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without targetable mutations using the algorithm – with Dr. Eric Singhi, Assistant Professor - University of Texas, MD Anderson Cancer Center.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Anne S. Tsao, MD, Mark A. Socinski, MD, Corey J. Langer, MD, Alan B. Sandler, MD, and David Gandara, MD, discuss the need to perform a second biopsy to check for the loss or acquisition of mutations in non-small cell lung cancer following progression.

For more from this conversation: http://www.onclive.com/peer-ex....change/nsclc-advance